Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

New drug development software initiative

Share this on social media:

Applied Biosystems and its partner MDS SCIEX have created a new software development initiative to help pharmaceutical companies determine drug candidate viability early in the development pipeline through better analysis of the absorption, distribution, metabolism and excretion (ADME) properties of compounds. The new software developments will improve the speed and accuracy of ADME testing of drug candidates, helping to lower the costly drug failure rate during pre-clinical stages of the development cycle.

The Applied Biosystems/MDS SCIEX approach will create a more intuitive method for managing the screening of compounds by increased automation of the analytical process, particularly quantitative mass spectrometry tailored for drug discovery laboratories.

As part of the initiative, Applied Biosystems/MDS SCIEX is collaborating with Sound Analytics and Pfizer to design these software applications. Sound Analytics – a scientific applications company that has been working on automation features with Pfizer for six years – will provide expertise in early ADME software development while Pfizer, the world’s largest research-based pharmaceutical company, will provide the guidance to shape the requirements for the new ADME software applications.